ReviewMicroorganisms2023
Recent Trends in Antimicrobial Resistance among Anaerobic Clinical Isolates.
Review in Microorganisms, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 34 citations in OpenAlex.
- Systemic Antibiotics in the Surgical Treatment of Peri-Implantitis: Impact on the Salivary Microbiome.Journal of clinical periodontology · 2026Trial
- Efficacy and safety of levornidazole disodium phosphate injection in patients with intra-abdominal infections caused by anaerobic bacteria: a multicenter, randomized, single-blind, phase IV, non-inferiority trial (ANAEROGUARD study).BMC infectious diseases · 2026Trial
- Anaerobic bacteria: a neglected reservoir of mobile oxazolidinone resistance genes.Gut microbes · 2026Article
- Standardized In-house Protocol for Determining the Minimum Inhibitory Concentration (MIC) via Broth Microdilution for Natural Products Against Obligate Anaerobic Bacteria.Current protocols · 2026Article
- Beyond Antibiotics: Traditional Chinese Medicine and Flavonoids in the Management of Endometritis.Veterinary sciences · 2026Review
- Targeting Bacterial Infections in Periodontal Disease: From Conventional Antibiotics to Next-Generation Therapeutics.Antibiotics (Basel, Switzerland) · 2026Review
- Natural and synthetic antimicrobial peptides against anaerobic bacteria: A review of activities and mechanisms of action.Probiotics and antimicrobial proteins · 2026Review
- Oxygen and ROS Delivery for Infected Wound Healing and Future Prospects.Advanced healthcare materials · 2026Review
- Article
- The Diffusion of Intravenously Administered Cefuroxime and Metronidazole into the Peritoneal Fluid During Postoperative Period in Patients with Secondary Peritonitis Compared to Controls: A Pilot Study Using Peritoneal Microdialysis.Antibiotics (Basel, Switzerland) · 2026Article
- Article
- Atypical Presentation of an Odontogenic Brain Abscess Due to Eggerthella lenta and Bilophila wadsworthia Coinfection.Cureus · 2026Article
- Clinical Significance ofMicroorganisms · 2026Article
- Diagnostic value of metagenomic next-generation sequencing in deep neck space infections: a retrospective study of 32 patients.Frontiers in cellular and infection microbiology · 2026Observational
- Current landscape and challenges in anaerobic bloodstream infections: epidemiology, microbiology, and clinical management.Frontiers in microbiology · 2026Review
- Clinical and Epidemiologic Characteristics of Anaerobic Bacteria Originating from Blood Cultures: A Five-Year Retrospective Study.Infection and drug resistance · 2026Article
- Phylogenomics and Antimicrobial Resistance of ClinicalAntibiotics (Basel, Switzerland) · 2025Article
- Targeting Fusobacterium nucleatum in colorectal cancer: therapeutic strategies and future directions.Infectious agents and cancer · 2025Review
- Metronidazole-Loaded Chitosan Nanoparticles with Antimicrobial Activity AgainstPharmaceutics · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anaerobic bacteria are normal inhabitants of the human commensal microbiota and play an important role in various human infections. Tedious and time-consuming, antibiotic susceptibility testing is not routinely performed in all clinical microbiology laboratories, despite the increase in antibiotic resistance among clinically relevant anaerobes since the 1990s. β-lactam and metronidazole are the key molecules in the management of anaerobic infections, to the detriment of clindamycin. β-lactam resistance is usually mediated by the production of β-lactamases. Metronidazole resistance remains uncommon, complex, and not fully elucidated, while metronidazole inactivation appears to be a key mechanism. The use of clindamycin, a broad-spectrum anti-anaerobic agent, is becoming problematic due to the increase in resistance rate in all anaerobic bacteria, mainly mediated by Erm-type rRNA methylases. Second-line anti-anaerobes are fluoroquinolones, tetracyclines, chloramphenicol, and linezolid. This review aims to describe the up-to-date evolution of antibiotic resistance, give an overview, and understand the main mechanisms of resistance in a wide range of anaerobes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.